After HCT, memory CD8+ T-cells exert anti-leukemia effects by limiting the potentially dangerous effects of graft-versus-host disease (GvHD) [21,22], confirming that BM CD8+ cells are functionally distinct from those in other compartments and possess higher anti-tumor activity [23]. Here, CD8A is linked to leukemia.